MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism

M. Faisal, D. Sreenivasa, R. Jayachandran, R. Seetharam, R. Iyer, P. Kukkle (Bengaluru, India)

Meeting: MDS Virtual Congress 2020

Abstract Number: 1127

Keywords: Apomorphine, Levodopa(L-dopa), Parkinsonism

Category: Parkinsonism, Others

Objective: To assess the efficacy of apomorphine in identification of levodopa responsive atypical parkinsonism.

Background: Management of atypical parkinsonism is a challenge. Most of these patients end up with suboptimal trial of levodopa due to preconceived notions about the levodopa response in atypical parkinsonism, sometimes without any clear documentation of benefits. Can apomorphine, a short and rapid acting dopamine receptor agonist segregate these patients and thereof limit potential misuse of levodopa? Management of atypical parkinsonism is a challenge. Most of these patients end up with suboptimal trial of levodopa due to preconceived notions about the levodopa response in atypical parkinsonism, sometimes without any clear documentation of benefits. Can apomorphine, a short and rapid acting dopamine receptor agonist segregate these patients and thereof limit potential misuse of levodopa?

Method: Subjects diagnosed with atypical parkinsonism underwent apomorphine response test (ART). Those who showed at least 50% improvement on UPDRS III scores were considered to have positive response. The further response of these subjects to escalated levodopa dosages were reviewed.

Results: Nineteen atypical parkinsonism subjects (M:F- 15:4) with a mean age of 65.2 years (Range:51-75years) and duration of symptoms of 41.7 months (Range:4-84months) underwent ART.  Clinical diagnosis in these subjects included Multiple system atrophy (n-3), Progressive supranuclear palsy (n-4), Vascular parkinsonism (n-1), Atypical atypical parkinsonism (n-11). All of these subjects had poor/no subjective response to levodopa at assessment except for three.   6/19 subjects showed good response to ART (including one with partial subjective benefits). They included MSA (n-1) and Atypical atypical parkinsonism (n-5) with clinical response of 77.3%, 72.1%, 63.6%, 61%, 50% and 49.5% respectively on UPDRS III scores. Following escalation of levodopa in these six subjects 3 reported subjective benefits (LD dosage: 750mg,750mg,850mg), two were lost to followup and in one no benefit was noted (LD dosage:1500mg).

Conclusion: In atypical parkinsonism patients, ART can be used as potential instrument to assess whether escalation in levodopa can benefit their clinical symptoms. It also acts as biofeedback both to the patient, caregiver and physician to try higher dosages than conventional levodopa trials.

To cite this abstract in AMA style:

M. Faisal, D. Sreenivasa, R. Jayachandran, R. Seetharam, R. Iyer, P. Kukkle. Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/apomorphine-as-a-diagnostic-tool-to-identify-levodopa-responsive-atypical-parkinsonism/. Accessed May 21, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/apomorphine-as-a-diagnostic-tool-to-identify-levodopa-responsive-atypical-parkinsonism/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley